ACR Appropriateness Criteria® on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II
详细信息 查看全文
- 作者：Prajnan Das ; Andrea Ng ; Louis S. Constine ; Ranjana Advani ; Christopher Flowers ; Jonathan Friedberg ; David C. Hodgson ; Cindy L. Schwartz ; Richard B. Wilder ; Lynn D. Wilson ; Michael J. Yunes
- 关键词：Appropriateness Criteria® ; Hodgkin's lymphoma ; unfavorable prognosis ; radiation therapy ; chemotherapy
- 刊名：Journal of the American College of Radiology
- 出版年：2011
- 出版时间：May 2011
- 年：2011
- 卷：8
- 期：5
- 页码：302-308
- 全文大小：213 K
文摘
Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.